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Background: GABRB3 is a position candidate gene at chromosome 15q12 that has been implicated in the
neurobiology of autism spectrum disorders (ASD). The aim of this study was to examine the genetic association of
GABRB3 with ASD.
Methods: The sample consisted of 356 patients with clinical diagnosis of ASD according to the DSM-IV diagnostic
criteria and confirmed by the Autism Diagnostic Interview-Revised and 386 unrelated controls. We searched for
mutations at all the exonic regions and 1.6 Kb of the 5′ region of GABRB3 in the genomic DNA of all the participants
using the Sanger sequencing. We implemented a case-control association analysis of variants detected in this sample,
and conducted a reporter gene assay to assess the functional impact of variants at the 5′ regulatory region.
Results: We detected six known common SNPs; however, they were not associated with ASD. Besides, a total of 22
rare variants (12 at 5′ regulatory, 4 at intronic, and 6 at exonic regions) were detected in 18 patients and 6 controls. The
frequency of rare variants was significantly higher in the patient group than in the control group (18/356 versus 6/386,
odds ratio = 3.37, P = 0.007). All the 12 rare variants at the 5′ regulatory region were only detected in 7 patients, but not
in any of the controls (7/356 versus 0/386, Fisher’s exact test, P = 0.006). Two patients carried multiple rare variants.
Family studies showed that most of these rare variants were transmitted from their parents. Reporter gene assays
revealed that four rare variants at the 5′ regulatory region and 1 at exon 1a untranslated region had elevated reporter
gene activities compared to two wild type alleles.
Conclusions: Our data suggest rare variants of GABRB3 might be associated with ASD, and increased GABRB3
expression may contribute to the pathogenesis of ASD in some patients.
Trial registration: Clinical trial registration Identifier: NCT00494754
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Autism spectrum disorders (ASD) are a constellation of
neurodevelopmental disorders characterized by the defi-
cits in social reciprocity and language/communication
ability, and the presence of restricted interests and
repetitive behaviors [1]. The prevalence of ASD was esti-
mated approximately as 1 per 110 children, with a male-to-
female ratio of approximately 4:1 [2,3]. Genetic factors have* Correspondence: gaushufe@ntu.edu.tw
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unless otherwise stated.been found to play an important role in the etiology of
ASD [4-6].
Chromosome 15q11-q13 is a hot region of occurrence
of genomic DNA deletions and duplications that are
usually associated with developmental disorders in-
cluding ASD [7-9]. For example, deletion of paternal
segment 15q11.2-q12 is associated with Prader-Willi
syndrome that is characterized by obesity, short stat-
ure, and hypotonia, while deletion of maternal segment
of 15q11-13 is associated with Angelman syndrome
which is characterized by mental retardation, movement
disorder, and impaired language and speech development.
Both Angelman and Prader-Willi syndromes are liable to
have ASD [10]. Moreover, maternal duplication of 15q11-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ASD [11]. Hence, genes located at this region have been
considered to be potential candidate genes of ASD.
Gamma-aminobutyric acid (GABA) is the main inhibi-
tory neurotransmitter in the brain. A cluster of GABAA
receptor subunit genes, including GABRB3, GABRA5,
and GABRG3, which encode subunits β3, α5, and γ3,
respectively, were mapped to chromosome 15q12 [8].
Several lines of study indicate that an altered GABAergic
signaling pathway is associated with the pathogenesis of
autism [12]. For example, reduced expression of GABAA
receptor subunits including GABRB3 [13-17] and the
GABA synthesizing enzymes, glutamic acid decarboxyl-
ase (GAD) 65 and 67 were found in several brain regions
of patients with autism [18-20]. Mori and colleagues re-
ported dramatically reduced GABAA receptor binding in
the superior and medial frontal cortex of patients with
ASD using 123I-iomazenil (IMZ) single photon emission
computed tomography [21]. These data render GABAA
receptor subunit genes potential candidate genes of
autism.
Several genetic linkage and association studies have in-
vestigated the association of the three GABAA receptor
subunit genes at 15q11-13 with ASD. Cook and col-
leagues first reported linkage disequilibrium (LD) be-
tween autism and a genetic marker at GABRB3 [22].
This finding was replicated by some studies [23-25], but
not by others [26-29]. Menold and colleagues found two
genetic markers in the GABRG3 associated with autism
[30]. McCauley and colleagues conducted a LD analysis
of genetic markers spanning the 1-Mb of 15q12; they
found six markers across GABRB3 and GABRA5 nomin-
ally associated with autism [31]. In view of the clinical
heterogeneity of patients with ASD, several groups stud-
ied the genetic association of these GABAA receptor
subunit genes with subsets of ASD patients based on
particular phenotypes. For examples, Shao and col-
leagues reported increased linkage of GABRB3 locus
with autism in families sharing the high insistence-on-
sameness scores [32]. Similarly, Nurmi and colleagues
reported improved linkage of GABRB3 with autism in
subset families based on savant skills [33]. Warrier and
colleagues examined the association between 45 SNPs in
GABRB3 and Asperger syndrome; they found significant
association of three SNPs with Asperger syndrome and
multiple related endophenotypes of ASD [34]. Further-
more, Ma and colleagues investigated the genetic associ-
ation of 14 known GABA receptor subunit genes and
their interaction with autism. They concluded that the
genetic interaction between GABRA4 and GABRB1 in-
creased the risk of autism [35]. Investigating the inter-
action between the markers in four GABAA receptor
subunit genes in an Argentinean sample of ASD, Sesar-
ini and colleagues found that the genetic interactionbetween GABRB3 and GABRD was associated with an
increased risk of autism [36]. However, Ashley-Koch and
colleagues investigated the multi-locus effect of three
GABAA receptor subunit genes at 15q12 on autism but
they did not find any positive association [37]. Atypical
sensory sensitivity is one of the core features of patients
with autism [38] and Tavassoli and colleagues found an
association between genetic markers of GABRB3 and
tactile sensitivity in typically developing children, impli-
cating the involvement of GABRB3 in the atypical sen-
sory sensitivity in autism spectrum conditions [39]. In
addition, postmortem studies showed reduced GABRB3
expression in patients with autism [15,16]. Taken to-
gether, converging evidence from these studies supports
the idea that GABRB3 may be an important candidate
gene of ASD.
One study reported that mice deleted for all three sub-
unit genes (Gabrg3, Gabra5, and Gabrb3) mostly died at
birth with a cleft palate, and approximately 5% that sur-
vived exhibited neurological abnormalities. However,
mice lacking the expression of Gabra5 or Gabrg3 did
not show the neurological symptoms found in the mice
lacking the three genes [40]. Furthermore, mice with de-
letion or reduction of Gabra5 showed enhanced learning
and memory [41,42]. Mice lacking the Gabrb3 had epi-
lepsy phenotype and many behavioral abnormalities such
as deficits in learning and memory, poor motor skills,
hyperactivity, and a disturbed rest-activity cycle [43].
Gabrb3 deficient mice also manifested a wide range of
neurochemical, electrophysiological, and behavioral ab-
normalities that overlapped with the traits observed in
ASD [44]. DeLorey and colleagues found that Gabrb3
deficient mice exhibited impaired social and exploratory
behaviors, deficits in non-selective attention and hypo-
plasia of cerebellar vermal lobules [45]. Hence, the
phenotype of Gabrb3 deficient mice was considered to
represent a potential model of ASD [45]. Duplication of
chromosome 15q11-q13 accounts for approximately 1
to 3% of autism cases [11]. A mouse model of 15q11-13
duplication showed several behavioral abnormalities
that replicate various aspects of human autistic pheno-
types [46]. However, the relevance of Gabrb3 to the
behavioral phenotypes has not yet been addressed in
this animal model.
Prompted by these findings, we were interested to
know whether GABRB3 was associated with ASD in our
population. The study specifically aimed to investigate
whether there are variants at GABRB3 that may confer
increased risk to ASD in our population. To address this
issue, we conducted deep sequencing of 1.6 Kb of the 5′
region and all exons and their flanking sequences of
GABRB3 in a sample of patients with ASD and control
subjects from Taiwan using Sanger-sequencing. The
GABRB3 [GenBank: NG_012836.1] spans approximately
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The first two exons (exon 1a and exon 1) are alterna-
tively spliced exons of GABRB3 that encode an open
reading frame of 473 amino acids of isoform 2 and iso-
form 1, respectively. Although both isoforms have the
same amino acid numbers, they have different amino
acid sequences in their N-terminus. The sequencing ap-
proach basically followed the study conducted by Urak




All the subjects enrolled into this study were Han Chinese
from Taiwan. Patients with a clinical diagnosis of ASD
made by board-certificated child psychiatrists according
to the Diagnostic and Statistical Manual of Mental
Disorders-IV (DSM-IV) [1] were recruited from the
Children’s Mental Health Center, National Taiwan
University Hospital (NTUH), Taipei, Taiwan; the Depart-
ment of Psychiatry, Chang Gung Memorial Hospital
(CGMH), Taoyuan, Taiwan; and Taoyuan Mental Hospital
(TMH), Taoyuan, Taiwan. The clinical diagnosis of ASD
was further confirmed by interviewing the caregivers
(mainly parents) by qualified child psychiatrists using
the Chinese version of the Autism Diagnostic Interview-
Revised (ADI-R) [48,49]. The Chinese version of the ADI-
R, translated into Mandarin by Gau and colleagues [48,49],
was approved by Western Psychological Services in 2007.
Their parents also reported their autistic symptoms on the
Chinese version of the Social Responsiveness Scale (SRS), a
65-item rating scale with each item rated from 1 to 4 [50],
and the Chinese version of the Social Communication
Questionnaire (SCQ), a 40-item rating scale with each item
rated as ‘yes’ or ‘no’ [49].
A total of 356 patients (312 boys and 44 girls, mean
age: 8.84 ± 4.05 years) were recruited into this study.
The ADI-R interviews revealed the 356 patients scored
20.65 ± 5.97 in the ‘qualitative abnormalities in recipro-
cal social interaction’ (cut-off = 10), 14.99 ± 4.21 in the
‘qualitative abnormalities in communication, verbal’
(cut-off = 8), 8.31 ± 3.25 in the ‘qualitative abnormalities
in communication, nonverbal’ (cut-off = 7), and 14.99 ±
4.21 in the ‘restricted, repetitive and stereotyped patterns
of behaviors’ (cut-off = 3). Ninety-five point one percent
of the patients had abnormal development evident be-
fore 30 months of age. Among the 356 subjects with
ASD, 17 have been diagnosed with epilepsy (4.78%), 5
have been suspected of seizure (1.40%), and 22 have had
febrile convulsions (6.18%). Thirteen of them (3.65%)
had been currently diagnosed with epilepsy.
The parents of patients with ASD were clinically assessed
by well-trained interviewers who major in psychology and
those whose children with ASD had genetic findingsreceived psychiatric interviews by the corresponding author
to confirm whether they had ASD. They also reported on
the Chinese version of the Autism Spectrum Quotient
(AQ) [51] to screen for any autistic trait and the Chinese
version of Adult Self-Report Inventory-IV (ASRI-IV) [52]
to screen for any psychiatric symptoms according to the
DSM-IV diagnostic criteria.
A total of 386 unrelated control subjects (189 males,
197 females, mean age: 45.8 ± 12.5 years) were recruited
from the Department of Family Medicine of Buddhist
Tzu Chi General Hospital, Hualien, Taiwan. The current
mental status and history of mental disorders of the con-
trol subjects were evaluated by a senior psychiatrist
using the Mini-International Neuropsychiatric Interview
[53]. Those with current or past history of mental disor-
ders were excluded from the study. We did not check
whether they had a family history of mental disorders.
The study protocol was approved by the Ethics Com-
mittee of each hospital (NTUH: 9561709027; CGMH:
93-6244; TMH: C20060905; ClinicalTrials.gov number,
NCT00494754) and written informed consent was ob-
tained from the participants and/or parents after full
explanation of the protocol and reassurance of confiden-
tiality and voluntary participation. Due to ethical consid-
eration and human subject protection, we were not able
to recruit gender- and age-matched control subjects into
this study.
PCR-based direct sequencing
Genomic DNA was prepared from the peripheral blood
of each participant for PCR amplification. Thirteen
amplicons that cover 1.6 Kb of the 5′ region and 10
exons of the GABRB3 were generated from each individ-
ual and these amplicons were subjected to PCR-
based autosequencing using ABI autosequencer 3730
(PerkinElmer Applied Biosystems, Foster City, CA,
USA). Approximately 30 to 60 bp of the intronic region
flanking the exon-intron junction of each exon were
sequenced. All mutations identified in this study were
confirmed by repeating PCR and sequencing. The pri-
mer sequences, optimal PCR conditions, and the size
of amplicons are listed in the Additional file 1, and
the locations of these amplicons are illustrated in the
Additional file 2. The allele frequency of the variant greater
than 1% was defined as common variation, whereas that
less than 1% was defined as rare variation in this study.
Reporter gene activity assay
Genomic DNA prepared from peripheral blood cells was
used to construct the inserts for the reporter gene assay.
For common and rare variants at the 1.6 Kb of the 5′ re-
gion, a sense primer containing the KpnI recognition se-
quence and an antisense primer containing the XhoI
recognition sequence were used to PCR amplify the
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stream to the ATG starting site of GABRB3 exon 1a
(genomic DNA positions: chromosome 15: 27018917-
27020517). The 1.6 Kb amplicon was first cloned into
the pCR-Blunt II-TOPO vector (Invitrogen, Carlsbad,
CA, USA), then subcloned into the pGL3-enhancer vec-
tor (Promega, Madison, WI, USA) using In-Fusion HD
cloning kit (Clontech, Mountain View, CA, USA). For
the mutation g.-53G > T at exon 1, a sense primer con-
taining the KpnI recognition sequences and an antisense
primer containing the XhoI recognition sequences were
used for PCR amplification of a fragment of 597 bp from
genomic DNA nucleotide positions: chromosome 15:
27017866-27018462. The amplicon was first cloned into
the pCR-Blunt II-TOPO vector (Invitrogen, Carlsbad,
CA, USA), then subcloned into the pGL3-enhancer vec-
tor (Promega, Madison, WI, USA). The authenticity of
these clones was verified by Sanger sequencing.
Plasmids were transfected into an HEK293 or SKNSH
cell line in 24-well plates using Lipofectamine 2000
(Invitrogen, Carlsbad, CA, USA) following the manufac-
turer’s protocol manufacturer. At 30 hours after trans-
fection, cells were lysed and the luciferase activities
were measured and normalized against Renilla luciferase
using the Dual-Luciferase Reporter Assay System (Pro-
mega, Madison, WI, USA). Transfection of each plasmid
construct was conducted in quadruplicate in each re-
porter gene experiment, and the reporter gene experi-
ment was repeated three times. The ratio of firefly
luciferase to Renilla luciferase was used to represent the
normalized reporter gene activity of each construct.
Comparison of reporter gene activity among different
expression constructs was conducted using one-way
analysis of variance (ANOVA) with post-hoc Tukey test.
P < 0.05 was considered statistically significant.
Bioinformatic analysis
Variants at the 1.6 Kb of the 5′ region were assessed
by WWW Signal Scan (http://www-bimas.cit.nih.gov/
molbio/signal/). Missense mutations were analyzed using
PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/). Sec-
ondary structure analysis was conducted by CDM protein
secondary structure prediction server (http://gor.bb.iastate.
edu/cdm/). The evolutionary conservation of the mutation
was evaluated using PMut (http://mmb.pcb.ub.es/PMut/).
Synonymous mutations were assessed by RegRNA
(http://regrna.mbc.nctu.edu.tw/index1.php) to predict their
influence on splicing donor/acceptor sites. ESEFinder 3.0
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?pro-
cess=home) was used to analyze exonic splicing enhancer
motifs. The prediction of possible phosphorylation sub-
strate motif and phosphorylation binding motif was ana-
lyzed using PhosphoMotif Finder (http://www.hprd.org/
PhosphoMotif_finder).Statistical analysis
Deviation from the Hardy-Weinberg equilibrium was
assessed by the Chi-square test. Genetic Power Calculator
(http://pngu.mgh.harvard.edu/~purcell/gpc/) was used to
perform a post-hoc power analysis. Linkage disequilibrium
(LD) analysis was performed using Haploview version 4.2
[54] in which D’ was calculated using the method reported
by Lewontin [55] and haplotype block was defined by the
method described by Gabriel and colleagues [56]. Differ-
ences in allele, genotype, and estimated haplotype fre-
quencies between patients and controls were evaluated
using SHEsis (http://analysis.bio-x.cn/SHEsisMain.htm)
[57]. Comparison of reporter gene activity among different
expression constructs was conducted using one-way
ANOVA with post-hoc Tukey test.Results
Identification of common SNPs and association analysis
We identified six known common SNPs in this study.
The locations of these SNPs are illustrated in Figure 1.
The detailed allelic and genotypic frequencies of these
six SNPs, as well as the post-hoc power analysis are pre-
sented in Table 1. There were no significant differences
in the frequency of allele or genotype of these six SNPs
between patients and controls (Table 1). SNP rs3751582
was found to have a nominal association with ASD in
genotype (P = 0.013, Table 1), but not in allele frequency
analysis.
Linkage disequilibrium (LD) analysis showed signifi-
cant LD among five SNPs (rs4906902, rs8179184,
rs20317, rs20318, and rs8179186) that formed a haplo-
type block in both patient and control groups (Figure 2).
SNP rs20317 (g.-66C > G) was predicted to delete a
myosin-specific/(+)GTCGCC transcription factor (TF)
binding site (Additional file 3). Haplotype-based associ-
ation analysis revealed four estimated haplotypes de-
rived from these six SNPs, but they were not associated
with ASD (Additional file 4).Detection of rare variants
Besides common SNPs, we detected a total of 22 rare
variants in 18 patients and 6 control subjects, with a sig-
nificant higher frequency in the patient group than the
control group (18/356 versus 6/386, odds ratio = 3.37,
P = 0.007) (Table 2). These 22 rare variants include 12 at
the 5′ regulatory region, 4 at intronic regions, and 6 at
exonic regions. Notably, all the 12 rare variants at the 5′
regulatory region were only detected in 7 patients, but
not in any controls (7/356 versus 0/386, Fisher’s exact
test P = 0.006) (Table 2). Locations of these rare variants
and their distributions in patients and controls are illus-
trated in Figure 1.
Figure 1 Schematic genomic structure of the GABRB3 gene and the locations of genetic variants identified in this study. The black
boxes represent the protein-coding regions, while the open boxes represent the untranslated regions. SNPs identified in this study are listed
below the schematic genomic structure and displayed in purple text. The positions of SNPs in the exon 1a promoter are numbered from the ATG
start site. With regard to rare mutations, patient-specific mutations are displayed in red text, those discovered in controls only are displayed in
green text, and those identified both in patients and controls are displayed in black text. IVS: intervening sequence; F: phenylalanine, T: threonine,
S: serine, M: methionine, Y: tyrosine, H; histidine; del: deletion; ins: insertion.
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A total of 14 families were enrolled for family study.
Pedigrees of these 14 families are illustrated in Figure 3.
The sex (11 males and 3 females), age (5.5 to 18.2 years
old), full-scale IQ (57 to 140), subscores of the social
reciprocity, verbal and non-verbal communication and
behavioral domains assessed by the ADI-R, SCQ score,
and SRS score of these 14 patients are summarized in
Additional file 5. Based on the clinical assessment by the
corresponding author, all the parents of the 14 patients
did not have ASD except that the father of patient
U1745 had ASD and the father of patient U1452 had
autistic trait.
Starting from the 1.6 Kb of the 5′ end of the GABRB3,
a g.-1571T > C variant was detected in a female patient
(U1723, Figure 3a) with uncertain origin. This mutation
was predicted to generate a new gamma-IRE_CS/(+)
CTTGATCC TF binding site (Additional file 3).Patient U1452 (Figure 3b) had a mutant allele harboring
multiple variants at the 5′ regulatory region including an
11-bp insertion (g.-1533_-1526delCCTCATAGinsTCCAT
TAGACAAAAGTCTG), g.-1437G > T, g.-1090A > G, g.-
541T > C, g.-534C > T, g.-169T > G and a T186M at
exon 6. This complex mutant allele was transmitted
from his father and found in another unaffected sibling.
Based on clinical assessment, his father had some autis-
tic trait characteristics such as abnormal reciprocal so-
cial interactions, difficulty finding common topics at
conversation, lack of expression of his affection to or
sharing with his family, and obsession with routine and
rituals without meeting the DSM-IV diagnostic criteria.
His report on the Chinese AQ (28) did not reach the
cut-off (35) of very likely to have ASD in adults. Besides,
he did not demonstrate any DSM-IV psychiatric symp-
toms except schizoid personality trait based on clinical
assessment and his report on the Chinese ASRI-IV. All
Table 1 Genotype and allele frequencies of the six known SNPs and association analysis between the patient (n = 356)
and control (n = 386) groups




P (df = 2) Allele counts
(frequency)
P (df = 1) Power
(df = .1)
1/1 1/2 2/2 1 2
5′ region rs4906902 ASD T/C 168 (0.472) 140 (0.393) 48 (0.135) 0.304 476 (0.669) 236 (0.332) 0.226 37.4%
Control 161 (0.417) 171 (0.443) 54 (0.140) 493 (0.639) 279 (0.361)
rs8179184 ASD G/A 168 (0.472) 141 (0.396) 47 (0.132) 0.342 477 (0.670) 235 (0.330) 0.244 37.3%
Control 162 (0.420) 171 (0.443) 53 (0.137) 495 (0.641) 277 (0.359)
rs20317 ASD C/G 167 (0.470) 140 (0.393) 49 (0.138) 0.327 474 (0.666) 238 (0.334) 0.347 37.6%
Control 162 (0.420) 172 (0.446) 52 (0.135) 496 (0.643) 276 (0.357)
Exon 1a rs20318 ASD C/T 167 (0.470) 139 (0.390) 50 (0.140) 0.220 473 (0.664) 239 (0.336) 0.406 37.7%
Control 161 (0.417) 175 (0.453) 50 (0.130) 497 (0.644) 275 (0.356)
Intron 3 rs8179186 ASD C/T 168 (0.472) 141 (0.396) 47 (0.132) 0.367 477 (0.670) 235 (0.330) 0.289 37.4%
Control 163 (0.422) 171 (0.443) 52 (0.135) 497 (0.644) 275 (0.356)
Intron 8 rs3751582 ASD G/A 195 (0.548) 126 (0.354) 35 (0.098) 0.013 516 (0.725) 196 (0.275) 0.131 34.0%
Control 217 (0.562) 152 (0.394) 17 (0.044) 586 (0.759) 186 (0.241)
Power indicates the estimates of power of risk alleles to detect the association with ASD under the assumptions of multiplicative inheritance mode, genotype
relative risk (Aa) = 1.2, prevalence of disease = 0.01, D’ = 1 and P-value of 0.05 under null hypothesis. df indicates degree of freedom. ASD, autism spectrum
disorders.
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T were predicted to generate new TF binding sites
(Additional file 3). The T186M missense variant at
exon 6 was predicted to be ‘probably damaging’ (Additional
file 3).
Patient U1733 (Figure 3c) had a g.-1528T > C variant
that was transmitted from his unaffected mother. The
variant was predicted to create a new TCF-1/(+)
CACAG TF binding site (Additional file 3). Both patient
U1745 and his bother suffered from ASD and had the
g.-1442G > A variant (Figure 3d). This mutation was not
detected in their mother. The father was clinically diag-
nosed as ASD by the corresponding author, a child
psychiatrist. His key features since childhood includedFigure 2 Plot of pair-wise linkage disequilibrium (LD) analysis and ha
(a) indicates LD plot of patient group, (b) indicates LD plot of controlspecial interest in digits, objects, and patterns, stereo-
typed routine and interest, inflexible schedule, avoidance
of any social interactions, difficulty figuring out what
others wanted or were addressing, and socially inappro-
priate conversation or manners. His report on the Chin-
ese AQ reached the cut-off of very likely to have ASD in
adults (35 > cut-off as 32). He did not have any experi-
ence of imaginary play. He also demonstrated anxious,
depressive, inattentive and schizoid symptoms based on
clinical evaluation and his report on the ASRI-IV. How-
ever, the father refused blood withdrawal; therefore, his
DNA was not available for testing. The g.-1442G > A
was predicted to create three new TF binding sites
(Additional file 3).plotype block of six SNPs of GABRB3 identified in this study;
subjects. D’ was shown in the plot.
Table 2 Comparison of the combined frequency of rare variants between the patient and control groups
Rare variants Patients (n = 356) Control (n = 386) Odds ratio P
All rare variants 18 6 3.37 0.007
5′ regulatory region 7 0 0.006 Fisher’s exact test
Intronic regions 4 2 2.18 0.36
Exonic regions 8 4 2.20 0.19
A patient had multiple mutations at the 5′ regulatory and a T186M missense mutation; hence, a total of 14 patients had the rare mutations.
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mitted from his father and this variant was also found in
his unaffected brother (Figure 3e). The g.-232G > T muta-
tion was predicted to delete a HiNF-A/(+)AGAAATG TF
binding site (Additional file 3). Patient U1067 had a
g.-142G > T mutation that was transmitted from his
unaffected father and this mutation was also found in his
unaffected brother (Figure 3f). The g.-142G > T mutation
was predicted to delete an AP-2/(+)CCGCCACGGC and
create a new LBP-1/(+)TCTGG TF binding site simultan-
eously (Additional file 3). Patient U985 had two variants,
g.-142G > T and g.-140A > T, that were transmitted from
his unaffected mother and unaffected father, respectively
(Figure 3g). The g.-140A > T was predicted to create a
new LBP-1 TF binding site.
Patient U838 had a c.51C > G variant at exon 1a that
was transmitted from his unaffected mother (Figure 3h).
This variant was also detected in his unaffected brother
and two controls. This variant did not alter amino acid
sequence at codon 17 (T17T) and was predicted to have
no functional influence (Additional file 3).
Patient U1143 had a g.-53G > T variant at the exon 1
untranslated region that was transmitted from his un-
affected father (Figure 3i). The variant did not alter any
TF binding site (Additional file 3).
Patient U1398 had a c.942C > T variant at exon 8 that
did not change phenylalanine at codon 314 (F314F)
(Figure 3j). This variant was transmitted from her un-
affected father and was not detected in any control sub-
ject in this study. This variant may influence the binding
of the serine/arginine-rich splicing factor 6 (SRSF6) to
an exonic splicing enhancer according to bioinformatic
analysis.
Patient U1915 had a c.1006C > T mutation at exon 8
that changed the proline to serine at codon 336 (P336S)
(Figure 3k). This mutation was transmitted from her un-
affected mother, and was also found in her unaffected
sister, but not in any control subject in this study. This
variant may affect the secondary structure and the phos-
phorylation of the protein (Additional file 3).
A c.1204T > C variant resulting in amino acid substi-
tution from tyrosine to histidine at codon 402 (Y402H)
was found in three patients and two controls in this
study. All three patients inherited this mutation from
one of their parent dyads (Figure 3l-3n). This variantwas already reported in the dbSNP with the number of
rs185383468 (minor allele frequency = 0.005). Bioinfor-
matic analysis predicted that this variant may affect the
secondary structure and the phosphorylation of the pro-
tein (Additional file 3).
Reporter gene assay
The results of reporter gene activity assay are shown in
Figure 4. In the experiment using the HEK293 cell line,
the g-232G > T and g-142G > T showed significant eleva-
tion of reporter gene activity compared to the wild type
construct CAG; however, they did not show significant
differences in reporter gene activity when compared to
the other wild type construct TGC (Figure 4a). In con-
trast, in the experiment using the SKNSH cell line,
variants g-1528T > C, g-1442G > A, g.-142G > T, and g-
140A > T showed significantly elevated reporter gene ac-
tivity compared to both wild type constructs (TGC and
CAG) (Figure 4b). In the assay of g-53G > T at exon 1
untranslated region, the mutant construct showed sig-
nificant elevation of reporter gene activity compared to
the wild type construct in both HEK293 (Figure 4c) and
SKNSH cell lines (Figure 4d).
Discussion
In this study, we identified a total of six common known
SNPs in this sample; however, no association of these
SNPs with ASD was detected. Due to the small sample
size of this study, the study has only approximately 34 to
37% power to detect the association under the assump-
tions of multiplicative inheritance mode and the geno-
type relative risk of 1.2. But in view of the clinical
heterogeneity of ASD, the possible association of these
SNPs with some subsets of patients cannot be ruled out.
During the sequencing experiment, we detected only
three common SNPs (rs4906902, rs8179184, rs20317) at
the 1.6 Kb of the 5′ regulatory region in our sample.
Urak and colleagues screened a sample of patients with
childhood absence epilepsy for mutations in the 10
exons and the 5′ regulatory sequences of GABRB3. They
found a total of 13 SNPs from the 5′ regulatory region
to the beginning of intron 3. Four different haplotypes
derived from these SNPs. Further, they found a SNP at
the 5′ regulatory region which changed the binding of a
neuron-specific transcriptional activator N-Oct-3 and
Figure 3 Pedigrees for 14 autism spectrum disorder (ASD) families carrying rare variants at 5′ regulatory and the protein-coding
regions of GABRB3. Arrow indicates the proband and asterisk denotes individuals for whom DNA was not available. F: phenylalanine,
T: threonine, S: serine, M: methionine, Y: tyrosine, H; histidine; del: deletion; ins: insertion.
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Figure 4 Reporter gene activity assay of variants at the 5′ regulatory region and exon 1a untranslated region found in this study.
(a) The mean ratio and standard deviation of firefly luciferase activity to Renilla luciferase activity of each construct expressed in HEK293 cell line.
No variant construct showed significant differences compared to both wild type constructs TGC and CAG simultaneously. (b) The mean ratio and
standard deviation of firefly luciferase activity to Renilla luciferase activity of each construct expressed in SKNSH cell line. *indicates four mutation
constructs including g-1528T > C (1.79 ± 0.60), g-1442G > A (1.99 ± 0.65), g.-142G > T (1.99 ± 0.65), and g-140A > T (1.62 ± 0.56) that showed significant
elevation of reporter gene activity compared to two wild type constructs TGC (0.37 ± 0.66) and CAG (0.66 ± 0.50) simultaneously (P < 0.05). (c) The
mean ratio and standard deviation of firefly luciferase activity to Renilla luciferase activity of the variant at exon 1a untranslated region measured in
HEK293 cells. The mutant allele had significant elevated reporter gene activity (1.34 ± 0.16) compared to the wild type (1.09 ± 0.16; P< 0.05). (d) Similarly,
the mutant allele showed significant reporter gene activity (4.18 ± 0.35) compared to the wild type (3.63 ± 0.28; P< 0.05) in SKNSH cells. MM indicates a
multiple mutation that was found in one patient. TGC and CAG are two major haplotypes of the 5′ regulatory region found in this study.
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assay [47]. Several SNPs at this region, such as rs4273008,
rs4243768, rs7171660, and rs4906901, as reported by Urak
and colleagues in Austrians [47], were not detected in our
sample. In addition, the rs4363842 as reported in Mexican
and people in Honduras [58] was not found in the study of
Urak and colleagues [47] and in our study. The three SNPs
found in our sample also showed variations in frequency
in different populations according to the dbSNP. Takentogether, these findings suggest that there might be a popu-
lation stratification of SNPs at the regulatory region of
GABRB3, which should be taken into consideration when
conducting a case-control association study of this gene.
Among these three SNP, the rs20317 was shown to be lo-
cated at the core promoter region of the GABRB3 and the
rs4906902 was located at the enhancer region. The C allele
of rs20317 has been shown to have a significantly increased
luciferase activity in a reporter assay [58].
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ple, including four variants (IVS1a + 10G > A, IVS1a +
17C > T, IVS1-3C > T, and IVS2-13G > C) located at
intronic regions (Figure 1). The functional impact of
these variants was predicted using bioinformatic ana-
lysis, and the results are listed in Additional file 3. The
frequency of rare variants in the patient group was sig-
nificantly higher than that in the control group, suggest-
ing that rare mutations of GABRB3 might be associated
with ASD. Of note, all the rare variants at the 5′ regula-
tory region were detected in the patient group only in
this study, with a significantly higher frequency in the
patient group than that in the control group. This find-
ing also implies that altered GABRB3 gene expression
might be involved in the neurobiology of ASD. The idea
was partly supported by the reporter gene activity assay in
this study. Four rare variants (g-1528T >C, g-1442G >A,
g.-142G >T, and g-140A >T) at the 5′ regulatory region
were shown to have elevated reporter gene activity com-
pared to the wild type alleles. The results are compatible
with our bioinformatic analysis that showed gain of tran-
scriptional binding sites of these four variants except g.-
142G >T. In addition to the gain of a LBP-1/(+)TCTGG,
the g.-142G >T was also predicted to lead to a loss of an
AP-2/(+)CCGCCACGGC binding site (Additional file 3).
Our data are also compatible with the increased Gabrb3 ex-
pression seen in the chromosomal-engineered mouse
model for human 15q11-13 duplication of autism [46].
GABRB3 is biallelically expressed in control brain tissue
samples. One study showed that the expression of GABRB3
was subject to epigenetic alterations that resulted in mono-
allelic expression in a subset of autism [59]. A recent study
reported significantly increased variance of GABRB3 ex-
pression in the brain of patients with 15q11-13 duplication
compared to control subjects and patients with autism [15].
Nevertheless, our findings are different from several post-
mortem studies that showed reduced GABRB3 expression
in the brains of patients with autism [14-16,60]. Hence, the
clinical relevance of our findings in this study remains to be
clarified.
In this study, we identified three missense mutations
(T186M, P336S, and Y402H) and two synonymous mu-
tations (T17T and F314F). The T17T is a new variant
that was detected in one patient and two controls in this
study, and appears to be neutral according to the bio-
informatic analysis. The F314F was detected in only one
patient but not in the controls in this study. Lachance-
Touchette and colleagues reported the detection of the
F314F synonymous variant in 1 out of 183 patients with
idiopathic generalized epilepsy (IGE), but not in the 190
controls [61]. The authors suggested this variant might
be pathological to IGE. This variant may influence the
binding of the serine/arginine-rich splicing factor 6 (SRSF6)
to an exonic splicing enhancer according to bioinformaticanalysis conducted in this study, but the clinical relevance
of this variant to ASD remains to be explored. The
three missense mutations identified in this study,
which occurred in the evolutionarily conserved region
of GABRB3, may affect the secondary protein structure
and alter a phosphorylation-based substrate motif or a
phosphorylation-based binding motif. These findings
suggest that these three missense mutations might
have a functional impact on GABRB3.
Family studies revealed that almost all the rare variants
found in patients were transmitted from their parents,
and not all the carriers of rare variants met the clinical
diagnosis of ASD, suggesting these rare variants are
more likely to be risk factors rather than causative
factors of ASD. Notably in the family of Figure 3g, the
affected male patient (U985) carried two variants
(g-142G > T and g.-140A > T) at the 5′ region of the
GABRB3 that were transmitted from his mother and
father respectively, lending the evidence to support the
multi-hit model of ASD [62,63].
We also identified a novel mutant allele that harbored
multiple mutations at the 5′ regulatory region and the
T186M at exon 6 in the patient U1452 and his father
(Figure 3b). Although the father did not meet the DSM-
IV diagnostic criteria of ASD, he manifested autistic
trait, suggesting this mutant allele might have a contrib-
uting effect to the pathogenesis of ASD. The T186M was
predicted to be probably damaging in bioinformatic ana-
lysis. As the T186M was linked to the multiple variants
at the 5′ regulatory region, and the reporter gene assay
showed no significant differences in the reporter gene
activity between the multiple regulatory variant alleles
and the wild type constructs, the T186M alone might be
the risk variant of ASD.
Missense mutations of GABRB3 have been reported to
be associated with childhood absence epilepsy (P11S, S15F,
G32R) [64,65], insomnia (R192H) [66], and autism (P11S)
[67]. In this study, we did not detect these missense muta-
tions in our samples. In addition, among our patients with
missense mutations, only the patient U1452 who carried
the T186M mutation had a history of abnormal electroen-
cephalography (EEG) in his childhood. The other patients
did not have a history of seizure. These findings indicate
that different mutations of GABRB3 may confer different
clinical presentations of neurodevelopmental disorders in
their carriers [68].
Conclusions
Our data suggest that rare variants of GABRB3 might be
associated with ASD, especially those at the 5′ regula-
tory region of GABRB3. Also, reporter gene activity
assay of variants at the 5′ regulatory region suggests that
increased GABRB3 gene expression might be associated
with the pathogenesis of ASD. Our study is limited by
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characterization of missense variants. Also, we found
the ratio of firefly luciferase activity to Renilla lucifer-
ase activity to be small and not consistent across
different experiments, suggesting that the expression
construct may not work well in this study. Hence, our
findings should be considered as preliminary and inde-
pendent replication studies with a larger sample size
are needed to verify our findings.
Additional files
Additional file 1: Primer sequences, optimal annealing temperature
(Ta) and size of amplicons of the GABRB3.
Additional file 2: Locations of PCR amplicons in this study. Double
arrow head dashed line indicates the location of the amplicon. The
amplicons for deep sequencing were shown in the upper panel of
schematic genomic structure of GABRB3, while the amplicons for reporter
gene assay were shown in the lower panel. E indicates exon.
Additional file 3: Summary of bioinformatic analysis of rare genetic
variants of GABRB3 identified in this study.
Additional file 4: Haplotype-based association analysis with ASD in
this study.
Additional file 5: Demographic and clinical profiles of 14 patients
with autism spectrum disorder who carried rare variants of GABRB3.
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